Creative Biolabs is a leading service company with a robust and standardized drug development
platform, supporting research and therapeutics in the psychiatric disorders field. Our experience in target research
and our psychotropic drug development background make us an excellent choice for norepinephrine transporter (NET)
antagonist development for our global customers.
As one of the crucial neurochemical messengers, norepinephrine (NE) plays an important role in human physiology and
pathology. It is involved in mood regulation, sleep regulation, expression of behavior, and the general degree of
alertness and arousal. NET, one of the monoamine transporters, is an integral membrane protein and is important in
regulating neurotransmission by uptaking the respective transmitters released from nerve terminals. The NET
regulation by substrates and inhibitors of the NET is a growing area of research because NET is an active site of
drugs. Therefore, NET serves as the primary mechanism for the inactivation of noradrenergic signaling and
constitutes the molecular targets for recreational drugs and therapeutics used to treat psychiatric disorders.
NET Antagonist with Psychiatric Disorders
The antagonist of the NET as an illicit psychostimulant drug is widely used in the treatment of psychiatric
diseases. Some potent and selective or mixed NET inhibitors (e.g., reboxetine and atomoxetine) have been
successfully developed to treat various mental disorders, including but not limited to depression and attention
deficit hyperactivity disorder (ADHD).
NET Antagonist Development at Creative Biolabs
The discovery of new potent and selective NET antagonists is important as it is expected to advance the diagnosis
and treatment of mental disorders and enhance our basic understanding of these illnesses. Creative Biolabs is an
indubitable leader in psychotropic drug development. Based on our well-established platforms, Creative Biolabs
offers customized NET antagonist services for the application of psychiatric therapeutic and imaging. We take
advantage of many approaches to help customers design the expected NET antagonist to support your psychotropic drug
development effectively.
Reboxetine is the
first truly selective NET inhibitor and is currently being marketed as an antidepressant in over 50 countries,
including Europe. The selectivity of reboxetine for the NET and its benign side effect profile results in the
drug being well-tolerated.
The potent NET
inhibitor atomoxetine is an effective and generally well-tolerated treatment for adults with ADHD. As a
non-stimulant, it is the first ADHD treatment to be explicitly approved for adult use based on its efficacy in
well-controlled adult trials.
The majority of
antidepressants used to treat major depressive disorder (MDD) are primarily antagonists at the NET and/or human
serotonin (SERT). As a selective dual NET/SERT antagonist, venlafaxine represents a new class of antidepressants
and has higher simultaneous effects on both 5-HT and NE. Another dual NET/SERT inhibitor, duloxetine is a
well-tolerated and even more effective antidepressant than venlafaxine.
With over a decade of experience and state-of-the-art drug development platforms, Creative Biolabs provides highly custom solutions for the NET antagonist to effectively support your therapeutics development. Please
do not hesitate to contact us by email or phone with your particular needs.
For Research Use Only.
